Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Edgewise Therapeutics
< Previous
1
2
Next >
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 26, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
June 06, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 11, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
May 02, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
March 30, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
March 21, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
March 14, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
March 06, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
March 01, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
February 28, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
February 07, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
January 04, 2023
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
December 21, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
December 20, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
October 27, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
October 13, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 27th International Hybrid Annual Congress of the World Muscle Society
October 06, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 13, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Proposed Offering of Common Stock
September 13, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
September 11, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
September 07, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
August 03, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
July 12, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
June 20, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference
June 16, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics to Present at Upcoming Investor Conferences
May 31, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
Edgewise Therapeutics Reports First Quarter 2022 Financial Results
May 11, 2022
From
Edgewise Therapeutics
Via
Business Wire
Tickers
EWTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.